Opinion

Video

Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)

Panelists discuss the current prevalence and treatment landscape of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC).

This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.

Patel provided an overview of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), the 2 most common types of nonmelanoma skin cancer. He explained that cSCC and BCC arise from keratinocytes in the epidermis and can present as rough, scaly patches or nodules that continue to grow and won’t heal. Pisano highlighted that cSCC and especially BCC are extremely common, with incidence rising as the population ages. She noted that cSCCis responsible for more cancer deaths annually than melanoma or Merkel cell carcinoma. Hamid then discussed immunotherapy with PD-1 inhibitors as a new standard of care for advanced cSCC and BCC. Hamid concluded that immunotherapy not only drives responses in advanced keratinocyte carcinomas but exhibits durability that could form the backbone of future combination regimens.

Video synopsis is AI-generated and reviewed by AJMC editorial staff. 

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo